What Living on My Own Has Taught Me

By Ella Balasa

Living alone has its perks and its downsides too. It can get quiet at times. There isn’t someone’s presence here constantly. The upside is having the flexibility of doing what I want on my own time. Although I have recently come to realize, more responsibility means less free time to do whatever I want whenever. Having CF, this means a lot more responsibilities. Many young adults are living with their parents through their early 20s. This is something I did as well, and have recently made the transition to being on my own. There are a few things I have learned so far:

Time management is important. I have to think through my day before it happens. Fitting in 3-4 breathing treatments a day is an absolute must, so everything else I do in a day has to be worked around when I do those. I have to think about when I need to do certain things to be able to get places at certain times and to accomplish what I need to do in a day. Nutrition is also extremely important, and to make sure I’m having healthy meals, not grabbing take-out on the way home or out, pre-planning meals is something I have to think about. For example, taking something out of the freezer the night before, so I can prepare it in a crockpot the next morning to be ready to eat by that evening. When I plan things I am able to accomplish more, in a more efficient way.

I’ve learned the meaning of discipline. This goes along with time management. There are times where I can’t go meet up with a friend because I need to be home doing treatments, cleaning nebulizing vials (we all know how tedious and annoying this can be) grocery shopping or taking care of other responsibilities. I no longer have my parents nagging me and reminding me to do tasks that I need to complete. I have to take the initiative and do without being told.

I have a greater appreciation for my parents. I now realize how much my mom did for me. Mostly cooking meals, cleaning the house, taking out the trash, and just her caring nature. When she would randomly bring me a snack as I typed away at my computer. It’s the little things like that I miss the most.

Freedom. This is the best positive aspect to the whole situation. I do love feeling the sense of independence and accomplishment that comes with figuring things out on my own, planning my days, and getting things done in the time they need to be. I wouldn’t trade it. It is nice to not have constant reminders from parents and nagging about things I’m doing wrong or what I should be doing. And I feel proud that I am able to live my own life despite the extra daily challenges.

Although it is more work to be responsible for myself, I think it’s a very important step for young adults including those with CF. Parents of children with CF can be quite overprotective and may have a harder time letting go and allowing young adults to manage their own lives. It teaches responsibility and discipline and in the long run is beneficial for CF adults as they are better prepared to take on more obstacles and challenges with managing life with CF.

Cystic Fibrosis Step by Step: Building a Treatment Routine

In this video, Gunnar stresses the importance of building a routine in order to stay compliant with his treatments and remain healthy. He also reminds listeners to keep an open dialogue with their doctors and support teams at CF Clinics. Continue reading Cystic Fibrosis Step by Step: Building a Treatment Routine

Advances in Inhaled Drug Delivery Offer Major Benefits to Patients, Chief Scientific Officer for Pulmatrix Explains in Article

Pulmatrix, Inc. (NASDAQ:  PULM) announced today that its Chief Scientific Officer, David L. Hava, PhD, has written an article in ONdrugDelivery Magazine highlighting advances in delivering drugs to the lungs to fight Continue reading Advances in Inhaled Drug Delivery Offer Major Benefits to Patients, Chief Scientific Officer for Pulmatrix Explains in Article

Raptor Pharmaceutical Launches QUINSAIR™ in Europe

http://www.nasdaq.com/press-release/raptor-pharmaceutical-launches-quinsair-in-europe-20160411-00214

First-in-Class Inhaled Fluoroquinolone Therapy for Cystic Fibrosis Patients
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced its first commercial sale of QUINSAIR™ (levofloxacin inhalation solution) in Continue reading Raptor Pharmaceutical Launches QUINSAIR™ in Europe

Capsugel and Pulmatrix Enter Collaboration to Develop and Manufacture Novel Inhaled Therapeutics

Capsugel and Pulmatrix, Inc. (“Pulmatrix”) (PULM) have formed a collaboration to develop novel inhaled therapeutics to treat serious pulmonary diseases. The agreement provides Capsugel exclusive rights to manufacture clinical trial and commercial batches of iSPERSE™-based inhaled Continue reading Capsugel and Pulmatrix Enter Collaboration to Develop and Manufacture Novel Inhaled Therapeutics

Arch Biopartners Receives Orphan Drug Designation from FDA for AB569

Arch Biopartners Inc., a portfolio based biotechnology company focused on developing innovative technologies that make a significant clinical impact on patients, today announced that the U.S. Food and Drug Administration (FDA) has Continue reading Arch Biopartners Receives Orphan Drug Designation from FDA for AB569

Columbia Engineering Team Develops Targeted Drug Delivery to Lung

New Method May Provide More Effective Treatments of Many Lung Diseases

Researchers from Columbia Engineering and Columbia University Medical Center (CUMC) have developed a new method that can target delivery of very small volumes of drugs into the lung. Their approach, in which micro-liters of Continue reading Columbia Engineering Team Develops Targeted Drug Delivery to Lung

Inhaled Mannitol Found to be Helpful for Those With Cystic Fibrosis

Several studies have recently been released looking at the use of dry mannitol powder in an inhalation device for the management of cystic fibrosis. One study, entitled “Optimising inhaled mannitol for cystic fibrosis in an adult population,” Continue reading Inhaled Mannitol Found to be Helpful for Those With Cystic Fibrosis

Kitabis Pak One of Ten Notable Drug-Device Approvals of 2014

Kitabis Pak, the first co-packaging of generic tobramycin inhalation solution with a PARI LC PLUS Nebulizer for cystic fibrosis, was among ten notable drug-device approvals of 2014 published in the current issue of Drug Development & Continue reading Kitabis Pak One of Ten Notable Drug-Device Approvals of 2014

PARI Pharma’s Vantobra Granted Marketing Authorisation in Europe

PARI Pharma’s Vantobra®, a new highly concentrated tobramycin nebuliser solution for inhalation delivered by a Tolero® nebuliser, was granted Marketing Authorisation from the European Commission in mid-March. Vantobra is a breakthrough for cystic fibrosis patients as it offers Continue reading PARI Pharma’s Vantobra Granted Marketing Authorisation in Europe